The invention provides a recombinant protein which is obtained by taking nucleotide sequences of a 337 amino acid segment to 645 amino acid segment for expressing an HEV (Hepatitis E Virus) ORF2 C section as target segments, utilizing primers to amplify the target segments, connecting a pMAL-c5X vector to obtain pMAL-c5X-ORF2 recombinant plasmids and carrying out prokaryotic expression. The protein can be reacted with a swine hepatitis E virus antibody; a liquid-phase chip detection technology is established by utilizing the protein and a cross reaction with positive serum of other common swine diseases does not occur; intra-assay and inter-assay variation coefficients are 5 percent and 6.6 percent respectively. A detection result of 102 clinical serum samples shows that the coincidence rate of the method and a commercialized ELISA (Enzyme Linked Immunosorbent Assay) kit is 93.1 percent; an associated chi-square test shows that two methods have the consistency (P is smaller than 0.01). The research provides a novel specific and sensitive rapid detection technology for clinical detection of the HEV serum antibody and a foundation is provided for a swine disease multiplex detection method.